Skip to main content
. 2017 May 10;8(30):49548–49563. doi: 10.18632/oncotarget.17747

Figure 2. Proposed risk stratification algorithm based on cytogenetic and ELN risk classification refined by NKp30 status.

Figure 2

When incorporating NKp30 expression in the integrated risk classification of AML based on cytogenetic classification and mutational status (ELN classification), 17% patients (29% of intermediate ELN patients) were re-classified in the unfavorable-risk group.